Mazdutide: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 11 sources cited
Overview
Mazdutide (LY3305677/IBI362) is a novel dual GLP-1/glucagon receptor agonist developed by Eli Lilly (licensed to Innovent Biologics for China). Unlike tirzepatide (which targets GLP-1/GIP), mazdutide adds glucagon receptor agonism to enhance energy expenditure and fat oxidation alongside appetite suppression. It represents the next frontier in metabolic peptide therapeutics.
Mechanism of Action
Mazdutide activates both the GLP-1 receptor and the glucagon receptor through a single engineered peptide. GLP-1 receptor activation produces appetite suppression via hypothalamic satiety signaling, slowed gastric emptying, and enhanced glucose-dependent insulin secretion from pancreatic beta cells — mechanisms shared with semaglutide and tirzepatide. The glucagon receptor agonism component is the differentiator: glucagon activates hepatic glycogenolysis and gluconeogenesis, but more importantly for obesity treatment, it potently stimulates energy expenditure through brown adipose tissue activation, hepatic fatty acid oxidation, and thermogenesis. The combination means mazdutide reduces caloric intake (via GLP-1) while simultaneously increasing caloric expenditure (via glucagon) — a dual mechanism that theoretically produces greater weight loss than GLP-1 agonism alone. The GLP-1 component also counterbalances glucagon's hyperglycemic effects, maintaining glucose homeostasis.
Mazdutide Benefits: What the Research Shows
- Phase III GLORY-1 trial (2025, NEJM, n=610) in Chinese adults with overweight or obesity showed mazdutide 6 mg produced 14.0% mean body weight loss at 48 weeks (12.6% at week 32) vs. a 0.3% gain with placebo
- In separate trials in Chinese adults with a BMI of 30 or more, the 9 mg dose produced 12.8% weight loss at 24 weeks (Phase II) and 16.7% at 60 weeks (Phase III GLORY-2)
- Phase III trials in Chinese adults with type 2 diabetes (2026, Nature) confirmed significant HbA1c reduction alongside weight loss: 2.15 percentage points with 6 mg vs. 0.14 with placebo at 24 weeks
- Mazdutide received approval in China for long-term weight management (June 2025) and for type 2 diabetes (September 2025)
- In a head-to-head Phase III trial, mazdutide produced greater weight loss and HbA1c reduction than the GLP-1 agonist dulaglutide 1.5 mg; a glucagon-driven rise in energy expenditure is the proposed reason but has not been measured in published human studies of mazdutide
- Trials show improved liver enzymes, and mouse studies show reduced liver fat, likely related to glucagon's hepatic fat oxidation effects
Mazdutide Dosage
- Clinical trial doses: 3 mg, 4.5 mg, 6 mg, and 9 mg subcutaneous injection once weekly
- Dose escalation: start at 3 mg weekly for 4 weeks, then increase by 1.5–3 mg every 4 weeks to target dose
- Maintenance dose: 6–9 mg weekly based on tolerability and response
- Inject subcutaneously in abdomen, thigh, or upper arm — rotate sites weekly
- Not yet FDA-approved — currently in Phase III clinical trials
- Approved in China in 2025 for weight management (June) and type 2 diabetes (September)
- Dose escalation is critical to minimize GI side effects — do not skip titration steps
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Mazdutide Side Effects & Safety
Known Side Effects
- Nausea: one of the most common side effects (47–50% of participants on 9 mg; about 23% at 3–6 mg in a diabetes trial), usually mild-moderate and improves with dose stabilization
- Vomiting (about 14% at 3–6 mg in a diabetes trial; 37–53% on 9 mg), primarily during dose escalation phases
- Diarrhea and constipation (GI motility effects)
- Decreased appetite (intended therapeutic effect, but can be excessive in some patients)
- Injection site reactions
- Potential for hypoglycemia when combined with insulin or sulfonylureas
- Elevated heart rate (2–5 bpm increase, class effect of GLP-1 agonists)
- Theoretical concerns: pancreatitis, gallbladder disease, thyroid C-cell tumors (GLP-1 class warnings)
Safety Profile
Mazdutide's safety profile is still being established through ongoing Phase III trials. The GLP-1 receptor agonist class has well-characterized safety concerns: GI side effects (nausea, vomiting, diarrhea), pancreatitis risk, gallbladder disease, and a theoretical risk of medullary thyroid carcinoma based on rodent studies (a boxed warning on the US labels of semaglutide and tirzepatide). The glucagon receptor component raises unique considerations: potential for hepatic glycogen depletion, transient hyperglycemia (offset by GLP-1's insulin-stimulating effects), and increased heart rate. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis, and pregnancy. Not FDA-approved as of 2025 — available only through clinical trials or Chinese market. Those interested should discuss with their physician and monitor developments in the regulatory pipeline.
What to Expect
Weeks 1–4 (3 mg): Appetite suppression begins. Nausea is common but typically manageable. Weight loss of 2–4% may occur during initial titration. Weeks 5–8 (escalating dose): Appetite suppression intensifies. GI side effects may transiently worsen with each dose increase, then improve. Weight loss accelerates. Weeks 9–16 (target dose): Steady weight loss of 1–2% per month. Energy expenditure may be noticeably increased (feeling warmer). Blood glucose and HbA1c improve in diabetic patients. Weeks 17–24+: Approaching maximum weight loss for the treatment period. Clinical trials show about 11–13% total body weight loss at 24 weeks at 6–9 mg, rising to 14% at 48 weeks (6 mg) and about 17% at 60 weeks (9 mg). Metabolic parameters (lipids, liver enzymes, blood pressure) typically improve substantially. Weight regain is expected after discontinuation, as with all GLP-1 class medications.
Common Stacks
L-Carnitine
L-Carnitine enhances mitochondrial fatty acid oxidation, complementing mazdutide's glucagon-mediated fat oxidation and GLP-1-mediated appetite suppression
5-Amino-1MQ
5-Amino-1MQ targets adipocyte-level fat metabolism through NNMT inhibition, adding a third mechanism of fat loss to mazdutide's dual receptor approach
Storage & Handling
Store per manufacturer instructions — typically refrigerated at 2–8°C. Pre-filled pens should not be frozen. Protect from light. Check expiration dates. As a clinical/prescription medication, follow pharmacist guidance for proper storage and handling.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025.
- Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026.
- Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026.
- Guo L, Zhang B, Xue X, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026.
- Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023.
- Ji L, Jiang H, Cheng Z, et al. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial. Med. 2026.
- Shirley M. Mazdutide: First Approval. Drugs. 2025.
- Kamrul-Hasan ABM, Chatterjee S, Ashraf H, et al. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026.
- Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024.
- Gan L, Duan L, Zheng X. Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation. Pharmaceuticals (Basel). 2026.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026.
Related Peptides
Track Mazdutide in Your Protocol
Log your Mazdutide doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free